549 results on '"Neelapu, Sattva"'
Search Results
2. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
3. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy
4. List of Contributors
5. Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling
6. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial
7. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial
8. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma
9. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
10. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
11. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
12. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
13. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy
14. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease
15. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
16. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
17. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
18. Mechanisms of Resistance and Relapse After CAR-T Cell Therapy
19. Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL).
20. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma
21. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
22. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights
23. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
24. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma
25. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
26. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
27. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
28. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
29. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
30. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
31. Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial.
32. Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial.
33. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
34. The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy
35. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy
36. A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting Aspergillus fumigatus
37. Analysis of Colonic FDG Uptake and Association with Response and Toxicity to CART in LBCL Patients
38. Clinical Factors Associated with Failure to Manufacture Commercial CAR-T Cell Products Among LBCL Patients
39. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
40. CAR Treg cells: prime suspects in therapeutic resistance
41. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
42. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
43. A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed/refractory follicular lymphoma
44. Correction: IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma
45. Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1
46. Germline Determinants of Toxicity and Efficacy in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 Autologous CAR T-Cell Therapy
47. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study
48. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
49. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
50. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.